Abstract:The mammalian target of rapamycin is a serine-threonine kinase that regulates cell cycle progression. Rapamycin and its analogues inhibit the mammalian target of rapamycin and are being actively investigated in clinical trials as novel targeted anticancer agents. Although cyclin D1 is down-regulated by rapamycin, the role of this down-regulation in rapamycin-mediated growth inhibition and the mechanism of cyclin D1 down-regulation are not well understood. Here, we show that overexpression of cyclin D1 partially overcomes rapamycin-induced cell cycle arrest and inhibition of anchorage-dependent growth in breast cancer cells. Rapamycin not only decreases endogenous cyclin D1 levels but also decreases the expression of transfected cyclin D1, suggesting that this is at least in part caused by accelerated proteolysis. Indeed, rapamycin decreases the half-life of cyclin D1 protein, and the rapamycin-induced decrease in cyclin D1 levels is partially abrogated by proteasome inhibitor N-acetyl-leucyl-leucyl-norleucinal. Rapamycin treatment leads to an increase in the kinase activity of glycogen synthase kinase 3β (GSK3β), a known regulator of cyclin D1 proteolysis. Rapamycin-induced down-regulation of cyclin D1 is inhibited by the GSK3β inhibitors lithium chloride, SB216763, and SB415286. Rapamycin-induced G1 arrest is abrogated by nonspecific GSK3β inhibitor lithium chloride but not by selective inhibitor SB216763, suggesting that GSK3β is not essential for rapamycin-mediated G1 arrest. However, rapamycin inhibits cell growth significantly more in GSK3β wild-type cells than in GSK3β-null cells, suggesting that GSK3β enhances rapamycin-mediated growth inhibition. In addition, rapamycin enhances paclitaxel-induced apoptosis through the mitochondrial death pathway; this is inhibited by selective GSK3β inhibitors SB216763 and SB415286. Furthermore, rapamycin significantly enhances paclitaxel-induced cytotoxicity in GSK3β wild-type but not in GSK3β-null cells, suggesting a critical role for GSK3β in rapamycin-mediated paclitaxel-sensitization. Taken together, these results show that GSK3β plays an important role in rapamycin-mediated cell cycle regulation and chemosensitivity and thus significantly potentiates the antitumor effects of rapamycin.

Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells

The Role of GSK3β in Rapamycin-Mediated Cell Cycle Regulation

Role of Glycogen Synthase Kinase 3β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity

[Effects of Rapamycin on Prostate Cancer PC-3 Cells].

The histone H2B Arg95 residue links the pheromone response pathway to rapamycin-induced G1 arrest in yeast

Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases

The Phosphatase Mkp1 Is A Transcriptional Target Of P53 Involved In Cell Cycle Regulation

Rapamycin Inhibits Igf-1 Stimulated Cell Motility Through Pp2a Pathway

The Mtor–s6k Pathway Links Growth Signalling to DNA Damage Response by Targeting RNF168

Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins

Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway

The Effect of Rapamycin on DNA Synthesis in Multiple Tissues from Late Gestation Fetal and Postnatal Rats

Rapamycin Enhances Apoptosis and Increases Sensitivity to Cisplatin In-Vitro

Mammalian Target of Rapamycin Pathway Inhibition Enhances the Effects of 5-Aza-dc on Suppressing Cell Proliferation in Human Gastric Cancer Cell Lines

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Inhibitory effect of rapamycin on PI3K/AKT/mTOR signaling pathway in gastric adenocarcinoma MGC-803 cells

Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity